Folliculitis decalvans is characterized by a persistent, abnormal subepidermal microbiota.


Journal

Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549

Informations de publication

Date de publication:
03 2020
Historique:
received: 22 10 2018
revised: 03 02 2019
accepted: 18 02 2019
pubmed: 26 3 2019
medline: 28 9 2021
entrez: 26 3 2019
Statut: ppublish

Résumé

Folliculitis decalvans (FD) is a chronic inflammatory disease of unknown aetiology. Although Staphylococcus aureus, frequently found on lesional skin, is thought to play a causal role, the importance of its involvement remains controversial. To examine the role of S aureus, we compared superficial and subepidermal microbiota in 20 FD patients who had S aureus on lesional skin and in 20 healthy controls using culture techniques and genomic identification, before and after an anti-staphylococcal treatment; we also screened for S aureus virulence factors. When present on lesional skin, S aureus colonized non-lesional and subepidermal skin in 80% of cases. These data imply a break in the epidermal barrier integrity and that an abnormal non-lesional skin microbiota persists in FD. S aureus had no superantigenic toxin in 31% of cases and no toxin specificity. Clinical improvement obtained in most cases upon treatment was associated with the disappearance of S aureus in all studied areas, with an incomplete restoration of normal microbiota and a significant increase in negative bacterial samples. This persistent unbalanced, subepidermal microbiota may act as a reservoir of abnormal flora and explain the chronicity of FD, suggesting new avenues of research to restore normal microbiota.

Identifiants

pubmed: 30907453
doi: 10.1111/exd.13916
doi:

Substances chimiques

Superantigens 0
Virulence Factors 0

Banques de données

ClinicalTrials.gov
['NCT02157688']

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

295-298

Subventions

Organisme : French Ministry of Health
ID : PHRC 2011
Pays : International
Organisme : French Ministry of Health
ID : NCT02157688
Pays : International
Organisme : SVR company
Pays : International
Organisme : Phytosolba company
Pays : International

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

C Clavaud, R Jourdain, A Bar-Hen, M Tichit, C Bouchier, F Pouradier, PLoS One 2013, 8, e58203.
EA Grice, HH Kong, G Renaud, AC Young, GG Bouffard, RW Blakesley, TG Wolfsberg, ML Turner, JA Segre, Genome Res. 2008, 18, 1043.
E Brown, RP Wenzel, JO Hendley, J. Infect. Dis. 1989, 160, 644.
HH Kong, Trends Mol. Med. 2011, 17, 320.
B Lange-Asschenfeldt, D Marenbach, C Lang, A Patzelt, M Ulrich, A Maltusch, D Terhorst, E Stockfleth, W Sterry, J Lademann, Skin Pharmacol. Physiol. 2011, 24, 305.
B Matard, T Meylheuc, R Briandet, I Casin, P Assouly, B Cavelier-balloy, P Reygagne, J. Eur. Acad. Dermatol. Venereol. 2013, 27, 853.
AC Jahns, OA Alexeyev, Anaerobe 2016, 38, 47.
AC Jahns, OA Alexeyev, Exp. Dermatol. 2014, 23, 687.
JP Lavigne, P Riegel, Ann. Biol. Clin. 2015, 73, 113.
M Puhvel, MR Reisner, DA Amiriand, J. Invest. Dermatol. 1975, 65, 525.
JN Kearney, D Harnby, G Gowland, KT Holland, J. Gen. Microbiol. 1984, 130, 797.
M Bek-Thomsen, HB Lomholt, M Kilian, J. Clin. Microbiol. 2008, 46, 3355.
R Aly, S Levit, Rev. Infect. Dis. 1987, 9(Suppl 4), S341.
A Van Belkum, M Kools-Sijmons, H Verbrugh, J. Microbiol. Methods 2002, 48, 19.
J Josse, F Laurent, A Diot, Front. Microbiol. 2017, 8, 495.

Auteurs

Bruno Matard (B)

Centre Sabouraud, Hôpital Saint-Louis, Paris, France.

Jean Luc Donay (JL)

Service de Bactériologie, Hôpital Saint-Louis, Paris, France.

Matthieu Resche-Rigon (M)

Biostatistics Unit, SBIM, Hôpital Saint-Louis, APHP, Paris, France.
ECSTRA Team, INSERM U1153, Paris, France.
Université Paris 7-Diderot, Paris, France.

Anne Tristan (A)

CNR des Staphylocoques, Faculté de Médecine Lyon Est, INSERM U111, Lyon, France.

David Farhi (D)

Dermatology Office, Paris, France.

Clotilde Rousseau (C)

Service de Bactériologie, Hôpital Saint-Louis, Paris, France.

Severine Mercier-Delarue (S)

Service de Bactériologie, Hôpital Saint-Louis, Paris, France.

Bénédicte Cavelier-Balloy (B)

Service D'anatomopathologie, Hôpital Saint-Louis, Paris, France.

Philippe Assouly (P)

Centre Sabouraud, Hôpital Saint-Louis, Paris, France.

Antoine Petit (A)

Service de Dermatologie, Hôpital Saint Louis, Paris, France.

Martine Bagot (M)

Service de Dermatologie, Hôpital Saint Louis, Paris, France.

Pascal Reygagne (P)

Centre Sabouraud, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH